Homechevron_rightAll Peptideschevron_rightARA-290

verified_user

Safety data sheet

Standardized safety protocols and material specifications for professional use.

analytics

Certificate of Analysis

Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-ara-290-10mg

Official Product Data Sheet

ARA-290 (10mg)

Research Grade >99.1% Purity

Vial Contents

10 mg ARA-290 (lyophilized powder)

Includes

3 ml bacteriostatic water for reconstitution

Form

Freeze-dried white powder for optimal preservation and stability

Purity

≥99%, third-party verified (COA available)

Sequence

Pyro-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser

Molecular Formula

C₅₃H₈₈N₁₆O₂₃

Molecular Mass

1317.4 g/mol

CAS No.

1208243-50-8

Solubility

Reconstitutes with bacteriostatic water to ~3.33 mg/mL (3 ml per vial)

Storage

Lyophilized frozen at −20 °C; reconstituted refrigerated at 2–8 °C for up to 28 days

Authorized Resellers

Available through our trusted partners

verifiedVerified

123peptide.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new

verifiedVerified

Depeptidenwinkel.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new

View all authorized resellersshopping_cart

swipe_rightSwipe to see all tabs

Scientific Background

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin's helix-B region, designed to engage tissue-protective pathways without erythropoietic effects.

It selectively engages the innate repair receptor (IRR), a combination of EPOR and CD131, to encourage anti-inflammatory and tissue-protecting responses. Unlike full EPO, ARA-290 does not stimulate red blood cell production, avoiding related hematological side effects.

Clinical studies have demonstrated benefits for diabetic neuropathy and sarcoidosis-associated small-fiber neuropathy, including improvements in nerve fiber density, pain scores, and metabolic markers.

Provided strictly for research purposes into neuroprotection, inflammation control, and tissue recovery.

Intended Research Use

Neuroprotection and peripheral neuropathy research
Innate repair receptor (IRR) activation studies
Anti-inflammatory signaling and cytokine modulation
Small-fiber nerve regeneration research
Tissue protection across multiple organ systems

menu_bookScientific Publications

article

Lancet (2021)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide in adults with overweight or obesity

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/34798060/

article

J Neural Transm (2011)

Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/20500802/

article

J Neurotrauma (2013)

Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/23656173/

warning

FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.

Possible stacks with other peptides

Synergistic combinations for enhanced research outcomes

ARA-290 can be combined with other neuroprotective and regenerative peptides for comprehensive nerve health and anti-inflammatory research.

Cerebrolysin (60mg vial)

arrow_forward

myo-cerebrolysin-60mg

Optimal neuroprotective regeneration through complementary neurotrophic mechanisms.

BPC-157 (5mg vial)

arrow_forward

myo-bpc-157-5mg

Enhanced wound healing and anti-inflammatory effects for synergistic tissue protection.

TB-500 (5mg vial)

arrow_forward

myo-tb-500-5mg

Complementary tissue regeneration and recovery support via actin-binding pathways.

Thymosin Alpha-1 (10mg vial)

arrow_forward

myo-thymosin-alpha-1-10mg

Immune modulation synergy in neuropathy models.

Semax (10mg vial)

arrow_forward

myo-semax-10mg

Combined neuroprotection and cognitive support in neurological research.